These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17486678)

  • 21. Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
    Wroolie TE; Williams KE; Keller J; Zappert LN; Shelton SD; Kenna HA; Reynolds MF; Rasgon NL
    J Clin Psychopharmacol; 2006 Aug; 26(4):361-6. PubMed ID: 16855452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD.
    Cohen RM; Greenberg JM; IsHak WW
    JAMA Psychiatry; 2013 Mar; 70(3):343-50. PubMed ID: 23303512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
    Brown ES; Vigil L; Khan DA; Liggin JD; Carmody TJ; Rush AJ
    Biol Psychiatry; 2005 Dec; 58(11):865-70. PubMed ID: 15993860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram.
    Papakostas GI; Larsen K
    Eur Arch Psychiatry Clin Neurosci; 2011 Apr; 261(3):147-56. PubMed ID: 20859636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placebo response and antidepressant response.
    Alexopoulos GS; Kanellopoulos D; Murphy C; Gunning-Dixon F; Katz R; Heo M
    Am J Geriatr Psychiatry; 2007 Feb; 15(2):149-58. PubMed ID: 17272735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
    Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
    Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
    Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
    Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
    Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
    Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Rush AJ; Wisniewski SR; Zisook S; Fava M; Sung SC; Haley CL; Chan HN; Gilmer WS; Warden D; Nierenberg AA; Balasubramani GK; Gaynes BN; Trivedi MH; Hollon SD
    Psychol Med; 2012 Jun; 42(6):1131-49. PubMed ID: 22008447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
    Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
    J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.